IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer

OBJECTIVE: Src family kinase (SFK) activation circumvents epidermal growth factor receptor (EGFR) targeting in head and neck squamous cell carcinoma (HNSCC); dual SFK-EGFR targeting could overcome cetuximab resistance. PATIENTS AND METHODS: We conducted a Simon two-stage, phase II trial of the SFK i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oral Oncol
Autori principali: Stabile, L.P., Egloff, A.M., Gibson, M.K., Gooding, W.E., Ohr, J., Zhou, P., Rothenberger, N.J., Wang, L., Geiger, J.L., Flaherty, J.T., Grandis, J.R., Bauman, J.E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2017
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5944328/
https://ncbi.nlm.nih.gov/pubmed/28559019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2017.03.011
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi